Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Cardlytics, Inc. (CDLX)

On August 7, 2024, Cardlytics reported its financial results for the second quarter ended June 30, 2024, including a decrease of 9% year-over-year in revenue, stating “our results were challenged
by slower-than-anticipated billings growth coupled with higher consumer incentives.” The Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of
Directors. On this news, the price of Cardlytics shares declined by $3.94 per share, or approximately 57.1%, from $6.90 per share on August 7, 2024 to close at $2.96 on August 8, 2024.

If you purchased or otherwise acquired Cardlytics securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected], or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of
shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240812078802/en/

The Cardlytics Stock at the time of publication of the news with a fall of -6,40 % to 3,22USD on
Lang & Schwarz stock exchange (12. August 2024, 22:54 Uhr).